Voyager Therapeutics, Inc. Common Stock
VYGRVoyager Therapeutics, Inc. (VYGR) is a biotechnology company focused on developing gene therapies for neurological diseases. Utilizing its proprietary AAV (adeno-associated virus) platform, Voyager aims to deliver potentially one-time treatments for conditions such as Parkinson's disease, Rett syndrome, and other neurodegenerative disorders. The company emphasizes innovative approaches to develop therapies that can modify disease progression and improve patient outcomes.
Company News
Johnson & Johnson discontinued its Phase 2b AuTonomy study of posdinemab after the drug failed to show statistical significance in slowing clinical decline for early Alzheimer's disease patients.
Voyager Therapeutics expanded its Alzheimer's disease franchise by introducing a new gene therapy program targeting APOE, complementing existing tau and amyloid assets. The program aims to reduce APOE4 variant expression while delivering the protective APOE2 variant using an innovative IV-delivered TRACER capsid.
Voyager Therapeutics published data in Molecular Therapy demonstrating the ability of a novel AAV capsid, VCAP-102, to cross the blood-brain barrier and transduce various brain regions in rodents and non-human primates. The company also highlighted its next-generation CNS capsids and non-viral delivery approaches.
Voyager Therapeutics presented new preclinical data on its tau-targeting gene therapy VY1706 and anti-tau antibody VY7523 at the AD/PDâ„¢ 2025 conference. The data showed promising results in reducing tau levels and inhibiting tau spread in animal models, supporting the potential of these programs for the treatment of Alzheimer's disease.
Voyager Therapeutics reported progress in its tau silencing gene therapy VY1706 and anti-tau antibody VY7523 programs for Alzheimer's disease. The company also extended its cash runway into mid-2027 by discontinuing its VY9323 program for ALS.
